Skip to main content

Table 5 Percent of CIN cases estimated to be attributable to nine specific HPV types & any HPV type in prior US studies

From: Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women

    

% of Cases Estimated to be Attributable to Specific HPV types

 

Year

Author

N

Testing Method

HPV 6

HPV 11

HPV 16

HPV 18

HPV 31

HPV 33

HPV 45

HPV 52

HPV 58

Any HPV type*

CIN 1 30,31,39–41,43

             

2006

Srodon, M

36

PCR/Biopsy

2.8

2.8

11.1

16.7

5.6

5.6

5.6

2.8

2.8

100.0

2005

Hu, L†

45

PCR/Biopsy

  

6.4

2.2

3.1

0.0

2.2

12.2

7.2

87.0

2002

Evans, M†

28

PCR/Biopsy

4.5

3.6

7.1

3.6

7.1

3.6

3.6

7.1

0.0

100.0

1998

Aoyama, C

11

PCR/Biopsy

0.0

0.0

27.3

9.1

9.1

9.1

   

54.5

1998

Quade, B

30

PCR/Biopsy

3.3

3.3

10.0

3.3

6.7

0.0

0.0

0.0

0.0

73.3

1996

Isacson, C

40

PCR/Biopsy

5.0

10.0

        

Total

 

190

 

3.6

4.8

9.9

6.7

5.6

2.7

2.9

6.1

3.0

87.4

CIN 2/3 30,31,39–43

             

2006

Srodon, M

116

PCR/Biopsy

0.0

0.0

75.0

4.3

5.2

1.7

0.0

0.9

3.4

100.0

2005

Hu, L†

97

PCR/Biopsy

  

38.9

9.6

11.6

1.0

1.1

5.0

2.6

93.6

2002

Evans, M

22

PCR/Biopsy

0.0

0.0

68.2

4.5

9.1

4.5

4.5

0.0

4.5

100.0

1998

Aoyama, C

21

PCR/Biopsy

0.0

0.0

52.4

0.0

19.0

19.0

   

95.2

1998

Quade, B

19

PCR/Biopsy

0.0

0.0

52.6

5.3

0.0

15.8

0.0

0.0

0.0

78.9

1996

Isacson, C

11

PCR/Biopsy

0.0

0.0

45.5

0.0

18.2

9.1

0.0

0.0

0.0

100.0

1993

Shroyer, K

13

PCR/Biopsy

0.0

0.0

61.5

0.0

     

92.3

Total

 

299

 

0.0

0.0

58.1

5.5

8.8

4.2

0.8

2.2

2.8

95.9

  1. * As determined by consensus PCR primers sensitive to positivity for at least 10 HPV types.
  2. † Lesions in these studies containing multiple HPV types were fractionally attributed to individual HPV types as described in the Methods section. Without this method of attribution, original figures for HPV prevalence differing from those reported in the table were as follows: Evans et al., CIN 1 (HPV 6 – 7.1%); Hu et al., CIN 1 (HPV 16 – 8.9%, 31 – 6.7%, 52 – 13.3%, 58 – 11.1%), CIN 2/3 (HPV 16 – 40.2%, 18 – 12.4%, 31 – 13.4%, 45 – 2.1%, 52 – 8.2%, 58 – 6.2%)
  3. CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; PCR = polymerase chain reaction